Oct 8, 2012
|
AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.
|
May 24, 2012
|
Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012
|
Apr 1, 2012
|
"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
|
Aug 31, 2011
|
Ardelyx, Inc. Closes $30M Series B Financing
|
Aug 31, 2011
|
Ardelyx Appoints Mark Kaufmann to Chief Business Officer
|